Roche in the news

Swiss stocks fell ahead of the US Fed rate decision, with cautious investors watching for policy signals; Nestlé's chairman resigned early, and pharma stocks showed mixed results.

Roche presents positive results for the cancer immunotherapy Tecentriq combined with Lurbinectedin, advancing personalized cancer treatment.

Swiss stocks fell slightly amid US tariff threats and strong US job data, with pharma stocks like Novartis and Roche declining due to drug trial setbacks and tariff concerns.

Roche reported increased revenue and profit in the first half of the year with positive future outlooks.

Roche's first-half revenue grew 4% to 31 billion CHF with an 8% rise in earnings per share, surpassing expectations despite currency challenges.

Roche's pharmaceutical division is steadily growing despite challenges from US healthcare policies affecting forecasts.

Roche received EU approval for a novel blood test to detect Alzheimer's and for a new breast cancer drug targeting specific mutations.

Analysts mostly recommend selling Roche stock with a slight expected price increase to 268 CHF.

Roche introduced a more accurate heart attack detection test, operating in pharma and diagnostics across multiple health areas.

Roche's stock traded near previous levels with stable dividends and expected earnings of 19.99 CHF per share in 2025.

Roche's stock gained 1.3% to 262.70 CHF with expected dividends and upcoming Q2 earnings reports in 2025 and 2026.

Roche's stock dropped 1% midday to 253.10 CHF, with analysts forecasting a 9.94 CHF dividend and 19.74 CHF earnings per share for 2025.

Roche's experimental COPD drug Astegolimab showed mixed late-stage trial results, with some efficacy but also study failures, prompting regulatory discussions.

JPMorgan keeps Roche shares underweight due to mixed study results for Astegolimab in COPD, suggesting limited market potential.

Roche's COPD drug Astegolimab failed its key Phase-3 trial, causing uncertainty about its efficacy and regulatory approval prospects.

Roche's stock declined midday, trading below its 52-week high with a slight dividend increase forecasted, and upcoming quarterly earnings reports scheduled.

Roche's stock rose 1.3% to 262.70 CHF with expected 2025 dividend of 9.92 CHF and upcoming Q2 earnings reports.

Roche's stock rose 1.2% to 262.40 CHF with upcoming Q2 financial results expected in July 2025 and 2026.

Roche's stock price increased by 1.2% to 262.40 CHF with upcoming Q2 financial results expected in July 2025.